Changing evidence on HIV treatment and prevention strategies: implications and advice for healthcare workers and National Treatment Programs in Asia

The articles in this special HIV issue of Asian Biomedicine focus on a series of important issues in resource limited settings in Thailand and across the rest of Asia where approximately 4.7 million people were living with HIV in 2008. It is comparatively only recently that many countries in Asia have been able to rapidly scale up access to antiretroviral agents through National Treatment Programmes. Many of the National Treatment Guidelines that have been developed in the process were based on the public health approach mandated by WHO in 2003 as part  of The Three by Five Initiative, designed for easy adoption by countries, irrespective of limited resources.

[1]  J. Ananworanich,et al.  Sexual life and contraception in people living with HIV , 2010 .

[2]  C. Beyrer,et al.  Biomedical prevention: what is the current status? , 2010 .

[3]  J. Elliott.  Second line antiretroviral therapy for treatment of HIV in Asia , 2010 .

[4]  J. Excler.  HIV-vaccines: lessons learned and the way forward , 2010, Current opinion in HIV and AIDS.

[5]  A. Hill.  d4T: keep it or abandon it? , 2010 .

[6]  M. Leechawengwong,et al.  Thai national guidelines for the prevention of motherto- child transmission of HIV: March 2010 , 2010 .

[7]  J. Ananworanich,et al.  Thai national guidelines for the use of antiretroviral therapy in pediatric HIV infection in 2010 , 2010 .

[8]  Praphan Phanuphak,et al.  Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010 , 2010 .

[9]  C. Königs,et al.  PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV‐1 infection , 2002, HIV medicine.

[10]  Somnuek Sungkanuparph,et al.  Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. , 2008, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[11]  C. Katlama,et al.  Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment , 2007, Expert opinion on pharmacotherapy.

[12]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[13]  James Curran,et al.  Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach , 2005 .

[14]  K. Stanecki,et al.  AIDS epidemic update December 2004. , 2004 .

[15]  Henry J. Kaiser,et al.  Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. , 1998, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[16]  J. Oleske,et al.  Guidelines for the use of antiretroviral agents in pediatric HIV infection , 1998 .